Lyell Immunopharma (LYEL) said Wednesday it has started a phase 3 head-to-head trial of LYL314 in patients with relapsed or refractory large B-cell lymphoma.
The study will evaluate LYL314 compared to liso-cel and axi-cel therapies in the second-line setting, the company said.
Lyell said LYL314 is a dual-targeting CD19/CD20 CAR T-cell therapy that has received Regenerative Medicine Advanced Therapy and Fast Track designations from the US Food and Drug Administration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.